Oreste Davide Gentilini
Overview
Explore the profile of Oreste Davide Gentilini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berton Giachetti P, Carnevale Schianca A, Trapani D, Marra A, Toss A, Marchio C, et al.
Cancer Treat Rev
. 2025 Mar;
135:102887.
PMID: 40048856
Multigene prognostic genomic assays have become essential tools in the management of early breast cancer (BC), providing information that help in risk-stratification, to provide risk-adapted decision-making of adjuvant treatments. Clinical...
2.
Banys-Paluchowski M, Hartmann S, Basali T, Gasparri M, de Boniface J, Gentilini O, et al.
Breast Cancer Res Treat
. 2025 Feb;
PMID: 39976867
Background: Surgical staging procedures of the axilla in initially clinically node-positive (cN +) breast cancer patients receiving neoadjuvant chemotherapy (NACT) vary across countries. Different procedures such as axillary lymph node...
3.
Gasparri M, Kaidar-Person O, Gentilini O, de Boniface J, Kuehn T, Poortmans P
Radiat Oncol J
. 2025 Jan;
42(4):308-318.
PMID: 39748531
Purpose: After primary systemic therapy (PST), agreement on the extent of locoregional therapy is lacking in breast cancer patients who convert from a node-positive to a node-negative status. The aim...
4.
Krawczyk N, Kuhn T, Ditsch N, Hartmann S, Gentilini O, Lebeau A, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39410007
Background: Idiopathic granulomatous mastitis (IGM) is a rare, benign inflammatory breast condition often mistaken for inflammatory breast cancer and, therefore, requires a biopsy for accurate diagnosis. Although not cancerous, IGM...
5.
Tvedskov T, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Frisell J, et al.
Lancet Reg Health Eur
. 2024 Oct;
47:101083.
PMID: 39386258
Background: Randomized trials have shown that axillary clearance (AC) can safely be omitted in patients with sentinel lymph node-positive breast cancer. At the same time, de-escalation of chemotherapy in postmenopausal...
6.
de Boniface J, Appelgren M, Szulkin R, Alkner S, Andersson Y, Bergkvist L, et al.
Lancet Oncol
. 2024 Aug;
25(9):1222-1230.
PMID: 39121881
Background: In luminal breast cancer, adjuvant CDK4/6 inhibitors (eg, abemaciclib) improve invasive disease-free survival. In patients with T1-2, grade 1-2 tumours, and one or two sentinel lymph node metastases, completion...
7.
Alkner S, Wieslander E, Lundstedt D, Berg M, Kristensen I, Andersson Y, et al.
Radiother Oncol
. 2024 Jun;
197:110372.
PMID: 38866204
Background And Purpose: Recommendations for regional radiotherapy (RT) of sentinel lymph node (SLN)-positive breast cancer are debated. We here report a RT quality assessment of the SENOMAC trial. Materials And...
8.
Schiavone A, Ventimiglia F, Zarba Meli E, Taffurelli M, Caruso F, Gentilini O, et al.
Eur J Surg Oncol
. 2024 May;
50(7):108351.
PMID: 38701582
Introduction: Neoadjuvant chemotherapy (NAC) has a profound impact on surgical management of breast cancer. For this reason, the Italian Association of Breast Surgeons (ANISC) promoted the third national Consensus Conference...
9.
Montagna G, Mrdutt M, Sun S, Hlavin C, Diego E, Wong S, et al.
JAMA Oncol
. 2024 Apr;
10(6):793-798.
PMID: 38662396
Importance: Data on oncological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast cancer that downstages from node positive to negative with neoadjuvant chemotherapy are sparse....
10.